The company specializes in mass spectrometry-based proteomics and has developed a technology to directly sequence antibody proteins without needing access to the producing cell line. Rapid Novor's REmAb™ service accurately sequences any given antibody proteins on a routine basis, while their WILD™ service is the first commercially available service that can distinguish between isobaric Isoleucine and Leucine using mass spectrometry. As a University of Waterloo spin-off, the company leverages over twenty years of scientific research and inventions. Their mission is to advance life science for better human health through next-generation protein sequencing. Rapid Novor provides antibody protein sequencing solutions to pharmaceutical companies, contract research organizations, and academic research institutions worldwide, delivering accurate and comprehensive results to help researchers make informed decisions.